Alcide Barberis

This inventor holds 22 USPTO granted patents and 6 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Antibody Engineering. Top assignees: Esbatech, an Alcon Biomedical Research Unit LLC, Esbatech Ag, Telormedix Sa. Active years: 2004-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alcide Barberis. Retrieved from https://idiyas.com/inventor/alcide-barberis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 6)

% Patents Active = 45.5

CIPO Patents = 6 (Patent Applications = 7)

EPO Patents = 13 (Patent Applications = 17)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 99(Granted Patents)

Location History:

Zürich, CH (2004 - 2015)
Olivone, CH (2015)
Uitikon, CH (2013 - 2016)
Bioggio, CH (2015 - 2017)
Bellinzona, CH (2017)
Zurich, CH (2007 - 2020)

Company Filing History:

8 out of 36

Esbatech, an Alcon Biomedical Research Unit LLC

Delenex Therapeutics Ag

patents

5. 1 out of 5

Cell Medica Switzerland Ag

patents

6. 1 out of 1

Esbatech, an Alcon Boimedical Research Unit, LLC

Years Active: 2004-2020

Loading Chart...

Areas of Expertise:

Antibodies

Immunoglobulin Frameworks

Phospholipid Drug Analogs

Stable Antibodies

Receptor Tyrosine Kinase

Intrabodies

Glioblastoma Treatment

TNF Inhibition

Nucleic Acids

Epithelial Passage

Screening Methods

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10570190 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2020-02-25),

2. 10125186 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2018-11-13),

3. 9683034 - Stable and soluble antibodies inhibiting TNFα (2017-06-20),

4. 9540407 - Phospholipid drug analogs (2017-01-10),

5. 9518108 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2016-12-13),

6. 9512411 - Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK (2016-12-06),

7. 9315572 - Stable and soluble antibodies inhibiting TNF alpha (2016-04-19),

8. 9180183 - Phospholipid drug analogs (2015-11-10),

9. 9173936 - Phospholipid drug analogs (2015-11-03),

10. 9173935 - Phospholipid drug analogs (2015-11-03),

11. 9050319 - Phospholipid drug analogs (2015-06-09),

12. 8945563 - Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK (2015-02-03),

13. 8936785 - scFv antibodies which pass epithelial and/or endothelial layers (2015-01-20),

14. 8853362 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2014-10-07),

15. 8691228 - Stable and soluble antibodies inhibiting TNFα (2014-04-08),

Title: Innovator Alcide Barberis: Pioneering Phospholipid Drug Analogs

Introduction

Alcide Barberis, an inventive mind based in Bioggio, Switzerland, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of five patents, Barberis has focused on developing phospholipid drug analogs that hold promise in medical applications.

Latest Patents

Among his latest innovations are compositions of compounds characterized by specific structures, as described in his patents. These compositions include pharmaceutically acceptable salts, tautomers, or hydrates, where the structural elements X, R, and n are meticulously defined. Furthermore, Barberis has outlined methods for preparing and utilizing these compounds, positioning his work at the forefront of pharmaceutical research.

Career Highlights

Throughout his career, Barberis has played vital roles in various companies within the biotechnology sector. Notably, he has been associated with Telormedix SA and Urogen Pharma Ltd., where he contributed his expertise to advance innovative solutions in drug development.

Collaborations

In addition to his corporate endeavors, Barberis has collaborated with esteemed colleagues such as Roberto Maj and Franco Pattarino. These partnerships have likely fostered an environment of creative synergy, enhancing the scope and impact of their research.

Conclusion

Alcide Barberis exemplifies the spirit of innovation in the pharmaceutical industry. His ongoing work on phospholipid drug analogs showcases his commitment to enhancing therapeutic options, ultimately benefiting practitioners and patients alike. As his research continues to evolve, it will be exciting to witness the future advancements stemming from his inventive contributions.

Profile summary based on public USPTO records.